BCRX
BioCryst Pharmaceuticals Inc
8.60$
+0.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -283.3% | -27.2% | -202.8% | -163.4% | -448.2% | -183.4% | -770.4% | -90.4% | -59.8% | -28.7% | -11.5% | 37.7% | |
| 1.3% | 0.4% | 1.8% | 2.8% | 3.7% | 1.5% | 4.2% | 0.5% | 0.5% | 0.5% | 0.3% | 0.2% | |
| 74.8% | 20.1% | 32.2% | 50.1% | 45.5% | 36.3% | 83.1% | 22.0% | 16.5% | 16.8% | 14.5% | 9.7% | |
| 35.8% | 21.3% | 29.2% | 53.9% | 50.6% | 37.0% | 86.6% | 21.0% | 52.4% | – | – | – | |
| 9.6% | 39.4% | -28.7% | 37.0% | -17.1% | -1.8% | 150.9% | 5.2% | -21.8% | -9.8% | -19.4% | -6.5% | |
| 0.8% | 10.6% | 20.0% | 1.3% | 1.8% | 0.7% | 2.9% | 1.5% | 0.5% | 0.7% | 0.2% | 0.3% | |
| -293.8% | -37.3% | 88.6% | -263.6% | 23.1% | 159.6% | -38.5% | 10.1% | -47.4% | -39.7% | 11.7% | -1.6% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 822.4% | 11.4% | 1.2% | 538.3% | 272.4% | 163.0% | 620.6% | 41.9% | – | – | – | – | |
| 168.9% | 47.6% | 86.0% | 0.5% | 30.6% | 39.9% | 378.7% | 187.0% | 27.0% | 17.6% | -0.4% | -34.5% | |
| 822.4% | 11.4% | 88.4% | 538.8% | 302.6% | 202.9% | 1,699.4% | 228.8% | 32.5% | 9.8% | -1.3% | -38.0% | |
| 245.3% | -53.1% | -25.8% | 111.9% | -122.5% | 179.1% | 890.6% | 148.5% | -74.4% | -58.5% | -1.4% | -11.8% | |
| -284.1% | -37.8% | -222.8% | -164.7% | -450.0% | -184.1% | -773.2% | -92.0% | -60.3% | -29.4% | -11.8% | 37.4% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.